Growth Real, Margins Unproven — The MHE Problem

Elecon's growth story is real. Q2 revenue of ₹638.9 crore grew 10.5% YoY, anchored by solid performance across Gear (+10.6%), MHE (+10.4%), and an impressive 30.6% surge in overseas business. The order book of ₹1,056 crores—up 37% YoY—provides the kind of H2 visibility that typically supports confidence. Yet the profit story trails. PAT grew just 9.8% YoY while revenue grew 10.5%, a 70-basis-point lag that masks a sharper problem underneath: MHE, the company's higher-margin second pillar, saw EBIT margins collapse from 27% to 20.2%—a 700-basis-point compression—even as volumes grew.

Management blamed Q2's MHE margin compression on two factors: project quality (order mix) and invoicing timing delays. Kaushik Patel, MHE Business Head, told investors that "the large part of the margin decline has been on the quality of the order" and flagged that clearances improving in Q2 mean "we will get a good amount of invoice as well from those projects" in coming quarters. The stated path to recovery is management's 22–24% EBIT guidance for H2, which would suggest a 200–400 basis-point bounce in the next two quarters.

The problem: there is no evidence yet. A 700-basis-point swing from one quarter to the next—blamed on timing and order mix but not quantified—asks the market to trust in a recovery without seeing the mechanics. If 20% proves to be the structural floor for MHE (say, if project delays extend, or if pricing power remains muted), then the 22–24% guidance is aspirational, and Elecon's path to the ₹5,000 crore FY30 target becomes sharply compressed on the margin side.

In Q1, management guided for "low double-digit" revenue growth in FY27 (roughly 10–12%). H1 delivered 11% YoY, tracking that guidance. On the Q2 call, they raised the bar to "mid-double-digit" for H2, implying ~15% growth in the second half. That upgrade is modest and credibly backed by the order book strength (+37%) and improved project clearances. However, the guidance came despite MHE margin deterioration, not resolved. Management maintained EBITDA margin guidance at FY26 levels (22%+) and MHE-specific guidance at 22–24% EBIT range, but neither has been proven in the quarter.

On the positive side, overseas momentum is accelerating as planned. Q2 overseas order inflow hit ₹230 crores (vs ₹194 Cr in Q1), and the division is now 27% of consolidated revenue—on track to the stated 50% by FY30. Gear margins also held firm at 22.1% EBIT (Q2 vs 20.2% LY), suggesting that price hikes and product mix improvements in the core division are delivering. This is the structural win under the quarter's headline numbers.

The market's initial reaction said it all. On day 1 after the October 14 announcement, the stock popped 1.26%, but by day 3, the bounce had reversed to a -5.38% drop. That fade is the street's verdict: growth and order book are fine, but the profit trajectory is unclear. The stock now trades at ₹433.25—down 41% from its all-time high and below its 20-day, 50-day, and 200-day moving averages.

Ownership flows are mixed. Foreign investors (FII) trimmed their stake by 15 basis points quarter-on-quarter to 6.99%, while domestic institutions (DII) added 151 basis points to 7.18%. This is a shallow accumulation by DIIs, not a ringing endorsement. Volume has increased, but the stock trades at a discount to its 52-week average and near the low of its recent range (₹352–₹579). For a company guiding 15% H2 growth and reaffirming a ₹5,000 crore FY30 target, a 41% drawdown from its all-time high could signal opportunity—or a warning that the margin recovery narrative is losing credibility.

The honest read: Elecon is a growth story with unproven profitability. The order book and export traction are real; the margin recovery is not yet evidenced. This is not a broken company—Gear is solid, overseas is scaling—but it is a company asking shareholders to trust in a rebound that has no track record yet. The market's skepticism (day-3 fade, FII trim, stock below averages) is rational. Holders and new buyers should wait for Q3 data on MHE clearances and invoicing to validate the recovery narrative.